HSU members push back against SESLHD job cuts

Following strong member action, the HSU can report some positive news on the Phase 2 Management Reduction Strategy at SESLHD.

When the original plan was put to the HSU in September, the reduction in staffing profile was proposed to be reduced by:

  • Health Managers 22.84 FTE
  • Administration Officers 20 FTE
  • Nurse Managers 4.63 FTE
  • Telephonists 23.69 FTE
  • Others 6.34 FTE (1 HSM 4 & 5.34 Nurse Unit Managers)

Since the release of the original document, HSU members have agitated successfully on the ground, approaching local politicians and campaigning against job losses for the benefit of health workers and the community.

Last Thursday, HSU representatives attended the second USCC meeting and were presented with a second version of the restructure document (Version 2A).                                                                       

The new version 2A document outlines the positions that have been saved because of member action:

  • Telephonist roles (23.69 FTE) have been saved at this point in time, with a review in March 2025.
  • Travel & Training Support Officer (1xAO4)
  • Research Business Manager (HSM 3)
  • Cashiers (1x AO6, 2xAO3, 1xAO4)
  • Clinical Stream Managers 5 x FTE
  • Finance Business Partner 1 x FTE

Of the 67.53 FTE outlined for deletion when the original plans were put to the HSU in September, HSU members have saved 35.69 FTE. Of the remaining 31.84 FTE that remain affected, the proposal has numerous new roles that these staff may be matched to or available to recruit to.

This a major win for HSU members and shows what we can do when we stand up together. However, we need to remain vigilant as changes are still being planned in the future, and the telephonists’ positions are still marked for review in early 2025.

You can view the updated documents at the below links:

If you have any feedback on these documents, please send it to [E-Mail not displayed] by COB Thursday 7 November with subject line SESLHD Management Reduction Strategy Phase 2A.